Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
223
resultados
Última actualización
02/11/2026 [07:28:00]
Resultados 50 a 75 de 223
Resumen de: US20260335250A1
Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
Resumen de: US20260337338A1
The use of novel polyoxyalkylene based compounds as well as the use of compositions including at least one novel polyoxyalkylene based compound and at least one active agent. Preferably the compounds and compositions are used as lipids, preferably in lipid particles or lipid nanoparticles and in pharmaceutical compositions.
Resumen de: US20260335252A1
Compositions and methods for treating wound healing are described using compositions comprising cellulose nanofibrils (CNFs) and hydrogels. Exemplified hydrogel-CNF compositions include blood-derived extracellular matrix-hydrogels comprising blood-derived growth factors, cytokines and ECM proteins wherein the treatment supports proliferation, differentiation, and migration capacity in wound healing and tissue regeneration.
Resumen de: WO2026222548A1
Vaccine candidates designed to protect poultry against infection with Salmonella enterica serovars include multiple antigenic polypeptide fragments of Salmonella iron acquisition proteins, such as the iron-regulated outer membrane proteins FepA, CirA, IroN and FhuA. The Salmonella antigenic polypeptides are displayed on the surface of protein nanoparticles, such as encapsulin or Brucella spp. lumazine synthase, and can be expressed in plants such as Nicotiana benthamiana.
Resumen de: WO2026227019A1
Disclosed are useful compositions and methods for enhancing cell transduction efficiency of a nanocarrier comprising a genetic payload that encodes a therapeutic agent. Embodiments of the present disclosure provide kits for transducing epithelial stem cells in a subject in need thereof. The present disclosure also provides methods of treating diseases of skin and mucous membranes in a subject using the disclosed compositions.
Resumen de: WO2026225085A1
One embodiment of the present invention provides a method for reducing the amount of NOx in a pharmaceutical additive. Alternatively, one embodiment of the present invention provides a pharmaceutical formulation production method in which a method for reducing the amount of NOx in a pharmaceutical additive is used. Alternatively, one embodiment of the present invention provides a pharmaceutical formulation in which a pharmaceutical additive having a reduced amount of NOx is used. A method for reducing the amount of NOx in a pharmaceutical additive according to one embodiment of the present invention includes irradiating a pharmaceutical additive with light having a radiant energy peak at 200-500 nm. Alternatively, a pharmaceutical formulation production method according to one embodiment of the present invention includes: reducing the amount of NOx in a pharmaceutical additive by using a method for reducing the amount of NOx in a pharmaceutical additive; and blending the pharmaceutical additive having a reduced amount of NOx with an active pharmaceutical ingredient. Alternatively, a pharmaceutical formulation according to one embodiment of the present invention contains: a pharmaceutical additive in which the amount of NOx has been reduced by using the method for reducing the amount of NOx in a pharmaceutical additive; and an active pharmaceutical ingredient.
Resumen de: WO2026223087A1
The present application relates to the technical field of biomedicine. Disclosed are a linker-small molecule compound and the use thereof. The linker-small molecule compound provided in the present application can be conjugated to an antibody to form an ADC drug, and particularly can be conjugated to socazolimab (a PD-L1 antibody) to form an ADC of socazolimab-linker-gimatecan, which has a DAR of 4-9, preferably 6-9, and more preferably 6.5 to-8. The ADC exhibits a IC50 value in the nanomolar range against human ovarian cancer cells, showing relatively strong pharmaceutical activity against the proliferation of ovarian cancer cells, and can be used in the preparation of an antibody-drug conjugate with an anti-cancer effect.
Resumen de: WO2026223088A1
The present application relates to the technical field of biopharmaceuticals. Disclosed are an antibody-drug conjugate, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. According to the chemical information, the DAR value of ADC socazolimab-linker-gimatecan provided in the present application is 4-9, preferably 6-9, and more preferably 6.5-8, and the IC50 thereof in human ovarian cancer cells is at the nanomolar level. The ADC demonstrates strong anti-proliferative activity against ovarian cancer and can be used for preparing antibody-drug conjugates having an anti-cancer effect.
Resumen de: US20260335463A1
Nucleic acid payload delivery systems, and related compositions and kits are provided. Aspects of such systems, compositions, and kits include lipid nanoparticle (LNP)—complexed payload DNAs and auxiliary RNAs. In some instances, the DNA and RNA components are part of the same LNP, while in other instances the DNA and RNA components are part of different LNPs. Also provided are methods of making and using such systems, compositions, and kits for the delivery of LNP complexed nucleic acids into cells, such as cells of a subject in vivo.
Resumen de: US20260337251A1
Provided here are novel engineered and isolated signal peptide sequences and compositions comprising these. Also provided are compositions and methods of using these signal peptides to enable secretion of heterologous polypeptides for therapeutic, diagnostic, and commercial value.
Resumen de: US20260335274A1
Pharmaceutical formulations for nasal administration are disclosed. The pharmaceutical formulation contains a green tea catechin derivative (such as an epigallocatechin-3-gallate-palmitate); and preferably further includes a carbohydrate (such as a polysaccharide); and a pharmaceutically acceptable carrier. The pharmaceutical formulation has a viscosity sufficient to maintain the green tea catechin derivative in contact with nasal epithelial cells optionally for at least about 30 minutes in the presence of mucus. Also described are methods of using the nasal formulations for preventing, reducing, and/or treating neurological damages caused by exposure to a virus, such as a SARS-CoV-2. For example, the disclosed pharmaceutical formulations can treat or prevent one or more symptoms of long COVID in an infected subject, and/or repair the damaged nasal epithelial cells, neuroepithelial cells, vascular cells, and/or neurons and restore their functions in a subject recovered from a COVID infection, such as the olfactory function of these cells.
Resumen de: US20260335237A1
The present disclosure relates to lipids, lipid nanoparticles and formulations thereof, and to methods involving the lipids and lipid nanoparticles to deliver one or more therapeutics and/or prophylactics to and/or produce polypeptides in mammalian cells or organs.
Resumen de: DE102025001356A1
Die vorliegende Erfindung betrifft eine Zusammensetzung zur lokalen Anwendung auf der Haut, umfassend mindestens eine mRNA, welche kodiert für ein oder mehrere Phagenenzyme sowie optional für Wachstumsfaktoren, verkapselt in Lipidnanopartikeln mit optionaler Zielsteuerung für Hautzellen. Die Zusammensetzung ist eingebettet in ein Hydrogel oder eine DMS-Trägerformulierung zur kontrollierten Freisetzung. Die Erfindung eignet sich zur Behandlung von infizierten Wunden, Akne und anderen Hauterkrankungen mit bakterieller Beteiligung sowie zur Förderung der Regeneration.
Resumen de: WO2026226857A1
The disclosure relates to immune cells for treatment of blood cancer comprising an activator receptor comprising an extracellular ligand binding domain specific to one or more activator antigens expressed by blood cancer cells and an inhibitor receptor comprising an extracellular ligand binding domain specific to one or more inhibitor antigens expressed by non-cancerous blood cells.
Resumen de: WO2026224636A1
A particular formulation approach for bacterial vesicle-based therapeutic compositions is described that opens the way for localized administration of such compositions, via topical application or intra-tumoral injection, which is efficacious against breakout cancer tumors that generally resist systemic therapy. -42-
Resumen de: WO2026226709A1
The disclosure provides methods of treating disorders of abnormal glycosylation (e.g., congenital disorders of glycosylation (CDGs)), including in individuals suffering from PMM2-congenital disorder of glycosylation (PMM2-CDG). In some aspects, provided is a method of treating PMM2-CDG in a subject in need thereof, comprising administering to the subject a composition comprising PMM2 mRNA.
Resumen de: WO2026226550A1
The present disclosure provides a composition containing a purified population of extracellular vesicles (EVs) isolated from one or more biological samples, wherein the purified population of EVs comprise a tuned cargo comprising a protein signature and an miRNA signature, wherein the tuned cargo of the purified population of EVs is a result of exposure of the one or more biological samples to one or more stress conditions that cause the one or more biological samples to modulate the EV cargo composition. The tuned cargo of the purified population of EVs can modulate bioactivities of recipient cells. The present disclosure also provides a method for improving appearance of human skin, treating eczema, promoting wound healing, promoting hair health, and promoting vaginal health, comprising applying a composition comprising the purified population of EVs comprising a tuned cargo and a carrier; and applying the composition topically.
Resumen de: AU2024444556A1
The present invention relates to a technology that aims to optimise the onset of action of a molecule having analgesic and anti-inflammatory properties, specifically celecoxib or derivatives thereof. The approach involves the production of nanocrystals of celecoxib or derivatives thereof stabilised with a low-viscosity polymer for a faster onset of action of the active ingredient, as well as the production process therefor, pharmaceutical compositions, uses and treatment methods comprising same.
Resumen de: AU2025251614A1
The present invention relates to lipid nanoparticles comprising ginsenoside or a derivative thereof, and use thereof, and, specifically, to: lipid nanoparticles containing vegetable ginsenoside or a derivative thereof included in ginseng or red ginseng, instead of animal cholesterol for the delivery of therapeutic or vaccine nucleic acids; gene-inorganic nanoparticles in which the corresponding lipid nanoparticles are encapsulated, and a preparation method therefor; and a nucleic acid delivery composition comprising same.
Resumen de: US20260335358A1
Provided are a Prussian blue composite, and a preparation method and use thereof. The Prussian blue composite includes hollow mesoporous Prussian blue nanoparticles, a liposome coating the hollow mesoporous Prussian blue nanoparticles, and an ammonia borane complex loaded on the hollow mesoporous Prussian blue nanoparticles.
Resumen de: US20260335251A1
In one aspect, this disclosure relates to nanoparticle compositions comprising a core a plurality of nanoparticles, each nanoparticle of the plurality comprising a core, wherein the core comprises a biocompatible copolymer, and each nanoparticle of the plurality further comprising an ionic liquid coating surrounding the core; methods of making the same; pharmaceutical compositions comprising same; and methods of treating neurological diseases and disorders using same. In one aspect, the biocompatible copolymer can be poly(lactic-co-glycolic acid). In another aspect, the nanoparticle compositions can include one or more pharmaceutical agents including, but not limited to, antiretroviral agents. In still another aspect, the ionic liquids can include choline and an anion derived from a substituted or unsubstituted C2-C20 linear or branched fatty acid. In any of these aspects, the nanoparticle compositions are capable of crossing the blood brain barrier.
Resumen de: EP4830735A2
0001 The present disclosure provides, in some aspects, virus-like particle drug conjugate formulations and use of the conjugates for treating ocular tumors or lesions.
Resumen de: WO2025078699A1
The current disclosure relates to targeted delivery of agents to T cells and/or NK cells. Highly suitable targeting domains were meticulously identified that allow for an agent, such as DNA and/or RNA, to be delivered to T cells and/or NK cells. As shown, when lipid nanoparticles were provided with such a targeting domain, nucleic acid comprised in said lipid nanoparticles was highly efficiently and specifically delivered. This allows for engineering of T cells and/or NK cells, highly useful in medical treatments for cancer.
Resumen de: WO2025147604A1
A composition for genetic editing of a hydroxyacid oxidase 1 (HAO1) gene, comprising: (a) a messenger RNA (mRNA) encoding a Cas12i2 polypeptide, (b) a guide RNA (gRNA) targeting the HAO1 gene; and (c) lipid excipients, which optionally form lipid nanoparticles. Also provided herein are methods for genetic modification of the HAO1 gene in host cells with the composition provided herein.
Nº publicación: EP4827875A2 28/10/2026
Solicitante:
UNIV MARYLAND [US]
TERASAKI INST FOR BIOMEDICAL INNOVATION [US]
University of Maryland, Baltimore
Terasaki Institute For Biomedical Innovation
Resumen de: WO2025137088A2
Cargo-free metabolite-based nanoparticles with high biocompatibility and low organ toxicity are provided to dampen pro-inflammatory responses while mitigating accompanying metabolic dysregulation in certain inflammatory conditions such as obesity and its metabolic sequelae such as type 2 diabetes. These nanoparticles are also useful as treatment for inflammatory and allergic conditions such as allergic airway inflammation. These nanoparticles are engineered from biodegradable polymers comprising endogenous bioactive metabolites, which upon cellular internalization are degraded into their monomeric components over time to elicit multimodal immunomodulatory functions without the need for frequent dosing, including inducing anti-inflammatory immune cell phenotypes, i.e., M2 macrophages.
BOPI
Sede Electrónica
